Tumor necrosis factor alpha–Tumor necrosis factor receptor superfamily member 1A interaction (TNF-alpha–TNFR1 interaction)

The interaction between Tumor Necrosis Factor alpha (TNF-alpha) and Tumor Necrosis Factor Receptor superfamily member 1A (TNFR1) is a fundamental signaling axis that regulates systemic inflammation and programmed cell death [1.1.3, 1.3.1]. TNF-alpha is a pleiotropic cytokine primarily produced by activated macrophages, while TNFR1 is a ubiquitously expressed receptor characterized by an intracellular death domain [1.1.1, 1.6.1]. Upon ligand binding, TNFR1 initiates complex signaling cascades: Complex I promotes cell survival and pro-inflammatory gene expression via NF-kappaB and MAPK pathways, while Complex II triggers apoptosis or necroptosis [1.1.3, 1.6.1]. TNFR1 is primarily activated by soluble TNF-alpha, whereas TNFR2 responds more strongly to the membrane-bound form, making the TNFR1 interaction a specific driver of systemic inflammation [1.3.1, 1.6.3]. Dysregulation of this interaction, specifically the chronic overproduction of TNF-alpha, is central to the pathogenesis of numerous autoimmune and inflammatory disorders, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease [1.2.1, 1.6.3]. Therapeutic intervention typically involves the use of biological agents, including monoclonal antibodies and decoy receptors, which neutralize TNF-alpha to prevent its engagement with TNFR1 [1.2.1, 1.2.4]. While these therapies have revolutionized the treatment of chronic inflammation, they are associated with significant safety concerns, most notably an increased risk of serious opportunistic infections, such as the reactivation of latent tuberculosis, and a potential risk for certain malignancies [1.4.1, 1.4.4].

Other names

Tumor necrosis factor alpha–Tumor necrosis factor receptor 1 interactionTNF-alpha–TNFRSF1A interactionTNF-alpha–CD120a interactionTNF-alpha–p55 interactionTNF-alpha–p60 interaction

Drugs targeting this interaction typically act as antagonists or neutralizers. Monoclonal antibodies (e.g., infliximab, adalimumab) and soluble receptor fusion proteins (e.g., etanercept) bind to TNF-alpha, preventing it from interacting with TNFR1 on the cell surface [1.2.1, 1.2.3]. This blockade inhibits the downstream pro-inflammatory and cell death signaling pathways, such as NF-kappaB, MAPK, and caspase cascades, which drive disease pathology [1.3.1, 1.6.1].